<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03683966</url>
  </required_header>
  <id_info>
    <org_study_id>AT-IIP-2018</org_study_id>
    <nct_id>NCT03683966</nct_id>
  </id_info>
  <brief_title>MigALastat Therapy Adherence Among FABRY Patients: A Prospective Multicentral Observational Study</brief_title>
  <acronym>MALTA-FABRY</acronym>
  <official_title>A Structured Survey Among Fabry Patients With a Focus on Adherence to Therapy, Quality of Life and Pain Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuerzburg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuerzburg University Hospital</source>
  <brief_summary>
    <textblock>
      This study evaluates adherence to the oral chaperone therapy migalastat in patients with
      Fabry disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fabry disease is a rare disease and part of the group of lysosomal storage disorders. Since
      2016, chaperone therapy as a new therapeutic approach is available.

      This study is a prospective cohort study and observes patients under therapy with migalastat.
      This study is suggested to help estimating the adherence of the oral therapy.

      All patients in treatment with migalastat in the Fabry Center Wuerzburg (FAZiT) and selected
      patients of other cooperating Fabry Centers are included in this study if informed consent is
      provided.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adherence to oral therapy with migalastat according to Morisky Score</measure>
    <time_frame>From date of inclusion up to104 weeks (2 years)</time_frame>
    <description>Pharmacological adherence according to Morisky Score. (Concurrent and Predictive Validity of a Self-Reported Measure of Medication Adherence Author(s): Donald E. Morisky, Lawrence W. Green and David M. Levine Source: Medical Care, Vol. 24, No. 1 (Jan., 1986), pp. 67-74 Published by: Lippincott Williams &amp; Wilkins Stable URL: http://www.jstor.org/stable/3764638) &quot;Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence&quot;, established by Donald E. Morisky, consists of 4 questions. Every question can be answered either with &quot;yes&quot; (0 points) or &quot;no&quot; (1 point), leading to a summed score between 0 and 4. 0 is the worst outcome while 4 is the best possible outcome (very good adherence). This part of the score can be used without special permission (Author was contacted via E-Mail).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life according to SF-36 and Wuerzburg pain questionnaire</measure>
    <time_frame>From date of inclusion up to104 weeks (2 years)</time_frame>
    <description>Change of quality of life under migalastat therapy according to SF-36 and Wuerzburg pain questionnaire. Short Form (36), abbreviated SF-36, is a disease-specific measurement tool for increasing the health-related quality of life. The SF-36 is composed of eight scale-valued domains that correspond to the weighted sums of answers in each section. The range of values of each scale is 0-100 under the assumption that each question has the same weight. A score of 0 is the worst outcome (maximum disability) and a score of 100 is the best outcome (no disability).
The eight domains of the SF-36 are vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain according to SF-36 and Wuerzburg pain questionnaire</measure>
    <time_frame>From date of inclusion up to104 weeks (2 years)</time_frame>
    <description>Change of pain under migalastat therapy according to SF-36 and Wuerzburg pain questionnaire.
The Wuerzburg pain questionnaire was created by Üçeyler et al. In this questionnaire, the patient's pain phenotype is characterized with questions about the presence of 1) permanent pain, 2) pain attacks, 3) pain crisis, and 4) evoked pain (by touching a cold or warm object or by pressure) in childhood and/or adulthood with the response options Yes, No, or Don't know. Other criteria can be found in the publication (Üçeyler N, Ganendiran S, Kramer D, Sommer C. Characterization of pain in fabry disease. Clin J Pain. 2014 Oct;30(10):915-20.).</description>
  </other_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Rare Diseases</condition>
  <condition>Fabry Disease</condition>
  <condition>Adherence, Medication</condition>
  <condition>Quality of Life</condition>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes every patient with Fabry disease and therapy who is seen in
        the FAZiT Wuerzburg. Limitation is a therapy with migalastat.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fabry disease (genetically confirmed)

          -  Signed informed consent

          -  18 years and older

        Exclusion Criteria:

          -  No informed consent

          -  Withdrawal of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Peter Nordbeck, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuerzburg University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Nordbeck, MD, PhD</last_name>
    <phone>004993120139181</phone>
    <email>nordbeck_p@ukw.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonas Muentze, MD</last_name>
    <phone>004993120139958</phone>
    <email>muentze_j@ukw.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wuerzburg University Hospital</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irina Schumacher</last_name>
      <phone>004993120139714</phone>
      <email>schumacher_i@ukw.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Müntze J, Salinger T, Gensler D, Wanner C, Nordbeck P. Treatment of hypertrophic cardiomyopathy caused by cardiospecific variants of Fabry disease with chaperone therapy. Eur Heart J. 2018 May 21;39(20):1861-1862. doi: 10.1093/eurheartj/ehy072.</citation>
    <PMID>29452394</PMID>
  </reference>
  <reference>
    <citation>Oder D, Liu D, Hu K, Üçeyler N, Salinger T, Müntze J, Lorenz K, Kandolf R, Gröne HJ, Sommer C, Ertl G, Wanner C, Nordbeck P. α-Galactosidase A Genotype N215S Induces a Specific Cardiac Variant of Fabry Disease. Circ Cardiovasc Genet. 2017 Oct;10(5). pii: e001691. doi: 10.1161/CIRCGENETICS.116.001691.</citation>
    <PMID>29018006</PMID>
  </reference>
  <reference>
    <citation>Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf El Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. N Engl J Med. 2016 Aug 11;375(6):545-55. doi: 10.1056/NEJMoa1510198.</citation>
    <PMID>27509102</PMID>
  </reference>
  <reference>
    <citation>Hughes DA, Nicholls K, Shankar SP, Sunder-Plassmann G, Koeller D, Nedd K, Vockley G, Hamazaki T, Lachmann R, Ohashi T, Olivotto I, Sakai N, Deegan P, Dimmock D, Eyskens F, Germain DP, Goker-Alpan O, Hachulla E, Jovanovic A, Lourenco CM, Narita I, Thomas M, Wilcox WR, Bichet DG, Schiffmann R, Ludington E, Viereck C, Kirk J, Yu J, Johnson F, Boudes P, Benjamin ER, Lockhart DJ, Barlow C, Skuban N, Castelli JP, Barth J, Feldt-Rasmussen U. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017 Apr;54(4):288-296. doi: 10.1136/jmedgenet-2016-104178. Epub 2016 Nov 10. Erratum in: J Med Genet. 2018 Apr 16;:.</citation>
    <PMID>27834756</PMID>
  </reference>
  <reference>
    <citation>Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, Bronfin B, Williams H, Yu J, Bichet DG, Germain DP, Giugliani R, Hughes D, Schiffmann R, Wilcox WR, Desnick RJ, Kirk J, Barth J, Barlow C, Valenzano KJ, Castelli J, Lockhart DJ. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017 Apr;19(4):430-438. doi: 10.1038/gim.2016.122. Epub 2016 Sep 22.</citation>
    <PMID>27657681</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 3, 2018</study_first_submitted>
  <study_first_submitted_qc>September 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2018</study_first_posted>
  <last_update_submitted>May 24, 2019</last_update_submitted>
  <last_update_submitted_qc>May 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuerzburg University Hospital</investigator_affiliation>
    <investigator_full_name>PD Dr. Peter Nordbeck</investigator_full_name>
    <investigator_title>Head Consultant Cardiology and Chief of Electrophysiology</investigator_title>
  </responsible_party>
  <keyword>Fabry</keyword>
  <keyword>Chaperone therapy</keyword>
  <keyword>Migalastat</keyword>
  <keyword>Pharmacological adherence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
    <mesh_term>Rare Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

